Roivant Sciences Ltd’s recently made public that its CFO Pulik Richard unloaded Company’s shares for reported $9.12 million on Dec 23 ’25. In the deal valued at $22.43 per share,406,731 shares were sold. As a result of this transaction, Pulik Richard now holds 239,413 shares worth roughly $5.2 million.
Then, Venker Eric sold 200,000 shares, generating $4,490,000 in total proceeds. Upon selling the shares at $22.45, the President & Immunovant CEO now owns 1,611,749 shares.
Before that, Venker Eric sold 75,000 shares. Roivant Sciences Ltd shares valued at $1,689,750 were divested by the President & Immunovant CEO at a price of $22.53 per share. As a result of the transaction, Venker Eric now holds 1,654,597 shares, worth roughly $35.9 million.
Citigroup initiated its Roivant Sciences Ltd [ROIV] rating to a Buy in a research note published on September 02, 2025; the price target was $16. Wolfe Research began covering ROIV with “an Outperform” recommendation on February 15, 2024. Piper Sandler started covering the stock on January 05, 2024. It rated ROIV as “an Overweight”.
Price Performance Review of ROIV
On Monday, Roivant Sciences Ltd [NASDAQ:ROIV] saw its stock fall -2.38% to $21.7. Over the last five days, the stock has lost -3.17%. Roivant Sciences Ltd shares have risen nearly 80.83% since the year began. Nevertheless, the stocks have risen 83.43% over the past one year. While a 52-week high of $23.47 was reached on 12/17/25, a 52-week low of $8.73 was recorded on 04/07/25.
Levels Of Support And Resistance For ROIV Stock
The 24-hour chart illustrates a support level at 21.48, which if violated will result in even more drops to 21.25. On the upside, there is a resistance level at 22.09. A further resistance level may holdings at 22.47.
How much short interest is there in Roivant Sciences Ltd?
A steep rise in short interest was recorded in Roivant Sciences Ltd stocks on 2025-12-15, dropping by -5.53 million shares to a total of 17.52 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 23.05 million shares. There was a decline of -31.56%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 12, 2023 when Deutsche Bank began covering the stock and recommended ‘”a Buy”‘ rating along with a $14 price target.
